Key result
Pre-existing LBBB in TAVR links to ~39% higher 2-year mortality versus no or new-onset LBBB.
Why the study?
Few reports exist on pre-existing LBBB in patients undergoing TAVR, and no studies had compared patients with new onset LBBB to those with pre-existing LBBB.
Does pre-existing LBBB increase mortality in patients undergoing TAVR compared to no LBBB or new onset LBBB?
Cohort (n=5,996)
Yes
Does pre-existing LBBB increase mortality in patients undergoing TAVR compared to no LBBB or new onset LBBB?
Effect estimate: adjusted HR 1.39 (95% CI 1.06-1.82)
p-value: p=0.015
Pre-existing LBBB is an independent predictor of 2-year all-cause and cardiovascular mortality after TAVR, conferring higher risk than both no LBBB and new-onset LBBB.
Pre-existing LBBB may identify higher-risk TAVR patients for closer surveillance; leaves open whether it should guide device selection or pacing in prospective trials.
Few reports on pre-existing left bundle branch block (LBBB) in patients undergoing transcatheter aortic valve replacement (TAVR) are currently available. Further, no present studies compare patients with new onset LBBB with those with pre-existing LBBB. This study aimed to investigate the association between pre-existing or new onset LBBB and clinical outcomes after TAVR. Using data from the Japanese multicenter registry, 5,996 patients who underwent TAVR between October 2013 and December 2019 were included. Patients were classified into 3 groups: no LBBB, pre-existing LBBB, and new onset LBBB. The 2-year clinical outcomes were compared between 3 groups using Cox proportinal hazards models and propensity score analysis to adjust the differences in baseline characteristics. Of 5,996 patients who underwent TAVR, 280 (4.6%) had pre-existing LBBB, while 1,658 (27.6%) experienced new onset LBBB. Compared with the no LBBB group, multivariable Cox regression analysis showed that pre-existing LBBB was associated not only with a higher 2-year all-cause (adjusted HR: 1.39; 95% CI: 1.06-1.82; P = 0.015) and cardiovascular (adjusted HR: 1.60; 95% CI: 1.04-2.48; P = 0.031) mortality, but also with higher all-cause (adjusted HR: 1.43, 95% CI: 1.07-1.91; P = 0.016) and cardiovascular (adjusted HR: 1.81, 95% CI:1.12-2.93; P = 0.014) mortality than the new onset LBBB group. Heart failure was the most common cause of cardiovascular death, with more heart failure deaths in the pre-existing LBBB group. Pre-existing LBBB was independently associated with poor clinical outcomes, reflecting an increased risk of cardiovascular mortality after TAVR. Patients with pre-existing LBBB should be carefully monitored.
No takes yet. Share an insight, caveat, or question.
Saito et al. (2024) conducted a cohort in Transcatheter aortic valve replacement (TAVR) (n=5,996). Pre-existing LBBB vs. No LBBB and new onset LBBB was evaluated on 2-year all-cause mortality (adjusted HR 1.39, 95% CI 1.06-1.82, p=0.015). Pre-existing LBBB in patients undergoing TAVR was associated with higher 2-year all-cause mortality compared to no LBBB (adjusted HR 1.39; 95% CI 1.06-1.82; P=0.015) and new onset LBBB.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: